Search companies

Live

Tuesday, 17 November 2026 · 581 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

BCAL Diagnostics Expands Breast Cancer Research With New Ethics Approval

BDX: $0.060 +0.00% · MC: $22M

BCAL Diagnostics has received ethics approval to expand its breast cancer research to multiomic assay development, including investigation of epigenomic biomarkers. Its lipidomics research framework has been published in a peer-reviewed journal, while a second paper remains under revision after peer review; an abstract on a blood-based assay for breast cancer recurrence has been accepted for a December symposium.

Source announcements: 2026-11-17 08:43 to 2026-11-17 08:43 Sydney time
Story updated 2026-11-17 08:49 Sydney time
SourcesBCAL Expands Breast Cancer Biomarker Program
Comments